If you want the full picture of trial results presented at medical meetings, you need to get your coverage from Elsevier Global Medical News. Here’s a good example of just one reason why.
This morning, I finished up a story about the first planned results from the TEAM trial, which showed a survival benefit for women with estrogen receptor-positive early breast cancer on adjuvant exemestane, compared with tamoxifen. The room was packed for the press conference, in which Dr. Stephen Jones presented some of the data. That’s the key word: some.
If you got your news about the trial from the many news outfits that reported from the press conference, you’d have missed an excellent additional analysis that was presented during the meeting presentation in the main hall yesterday morning. Dr. Jones noted that compliance, particularly with tamoxifen, is a problem for clinical trialists. Roughly a third of women on tamoxifen stopped taking the drug before the end of 2.75 years of follow-up. In an analysis of just patients who took the drug for the full follow-up period, disease-free survival was slightly better for those on exemestane than with the full intent-to-treat population analysis.
But you might not know that, depending on where you get your medical news. You can find the story on OncologyStat, for which EGMN is a primary news provider.